Patents by Inventor Peter Bohlen

Peter Bohlen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8143025
    Abstract: Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti-VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 27, 2012
    Assignee: ImClone LLC
    Inventors: Yan Wu, Peter Bohlen, Daniel J. Hicklin
  • Publication number: 20110269186
    Abstract: Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti-VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 3, 2011
    Applicant: IMCLONE LLC
    Inventors: Yan WU, Daniel J. HICKLIN, Peter BOHLEN
  • Patent number: 7972596
    Abstract: Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti -VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: July 5, 2011
    Assignee: ImClone LLC
    Inventors: Yan Wu, Danny J. Hicklin, Peter Bohlen
  • Publication number: 20100028347
    Abstract: Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti -VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies.
    Type: Application
    Filed: November 18, 2005
    Publication date: February 4, 2010
    Inventors: Yan Wu, Daniel J. Hicklin, Peter Bohlen
  • Publication number: 20090060909
    Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.
    Type: Application
    Filed: March 26, 2008
    Publication date: March 5, 2009
    Applicant: IMCLONE SYSTEMS INC.
    Inventors: Fang LIAO, Daniel J. Hicklin, Peter Bohlen
  • Publication number: 20080317750
    Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.
    Type: Application
    Filed: March 26, 2008
    Publication date: December 25, 2008
    Applicant: IMCLONE SYSTEMS INC.
    Inventors: Fang LIAO, Daniel J. Hicklin, Peter Bohlen
  • Publication number: 20080311121
    Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin. (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.
    Type: Application
    Filed: March 26, 2008
    Publication date: December 18, 2008
    Applicant: IMCLONE SYSTEMS INC.
    Inventors: Fang Liao, Daniel J. Hicklin, Peter Bohlen
  • Patent number: 7371574
    Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VIE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine ceH indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the prectinical development since its anti-tumor activity can be tested extensively in several mouse models.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: May 13, 2008
    Assignee: Imclone Systems, Inc.
    Inventors: Fang Liao, Daniel J. Hicklin, Peter Bohlen
  • Publication number: 20040247577
    Abstract: The present invention relates to methods of inhibiting heparanase activity and treating various conditions by administering to an animal an effective amount of an immunogen that elicits an immune response to heparanase. According to the present invention, the immunogen is heparanase or a fragment thereof and, preferably, the immunogen is an antigen presenting cell (APC), such as a dendritic cell (DC), displaying heparanase or a fragment thereof on the surface. The present invention also relates to compositions containing the immunogen.
    Type: Application
    Filed: June 16, 2004
    Publication date: December 9, 2004
    Inventors: Peter Bohlen, Daniel J. Hicklin, Paul Kussie, Yiwen Li
  • Patent number: 6511823
    Abstract: The invention relates to Novel DNA and amino acid sequences for a heparin bending neurotrophic factor, (HBNF). Also described are expression vectors and host cells useful in a method for production of the HBNF protein.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: January 28, 2003
    Assignee: American Cyanamid Corporation
    Inventors: Imre Kovesdi, Peter Bohlen
  • Publication number: 20020160003
    Abstract: This invention relates to antibodies, or immunologically active fragments thereof, specific for the N-terminal 15 amino acids of a mammalian VE-cadherin and which act as antagonists of VE-cadherin-mediated homophilic interactions between adjacent endothelial cells without adversely affecting normal vasculature. In a preferred embodiment, the antibodies are humanized antibodies directed that react with human VE-cadherin for use in a human. The invention also provides pharmaceutical compositions comprising these antibodies and antibody fragments, methods of preparing the antibodies, and methods of using the antibodies and antibody fragments to inhibit angiogenesis, inhibit tumor metastasis, or treat cell proliferative disorders.
    Type: Application
    Filed: January 2, 2002
    Publication date: October 31, 2002
    Inventors: Fang Liao, Daniel J. Hicklin, Peter Bohlen
  • Patent number: 6010999
    Abstract: The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing said derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 4, 2000
    Assignee: American Cyanamid Company
    Inventors: Michael Joseph Daley, Brian Lee Buckwalter, Susan Mancini Cady, Hong-Ming Shieh, Peter Bohlen, Andrew P. Seddon
  • Patent number: 5951972
    Abstract: The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing the derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: September 14, 1999
    Assignee: American Cyanamid Company
    Inventors: Michael Joseph Daley, Brian Lee Buckwalter, Susan Mancini Cady, Hong-Ming Shieh, Peter Bohlen, Andrew P. Seddon
  • Patent number: 5856315
    Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of 7-?substituted amino!-9-?(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: January 5, 1999
    Assignee: American Cyanamid Company
    Inventors: Joseph M. Backer, Peter Bohlen
  • Patent number: 5843925
    Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-?substituted amino!-9-?(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: December 1, 1998
    Assignee: American Cyanamid Company
    Inventors: Joseph M. Backer, Peter Bohlen
  • Patent number: 5641743
    Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps. The growth factors may be useful in the promotion of angiogenesis, such as in the promotion of wound healing, bone healing and in the treatment of burns, as well as in promoting the formation, maintenance and repair of tissue, in particular, neural tissue.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: June 24, 1997
    Assignee: American Cyanamid Company
    Inventors: Peter Bohlen, Peter Gautschi-Sova
  • Patent number: 5574026
    Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-halogen-9-[hydrogen or [(substituted glycyl)amido]]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: November 12, 1996
    Assignee: American Cyanamid Company
    Inventors: Joseph M. Backer, Peter Bohlen, Phaik-Eng Sum
  • Patent number: 5567693
    Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-(hydrogen or di (C.sub.1 -C.sub.4)alkylamino)-8-halogen-9-(substituted)-6-demethyl-6-deoxytetracycl ine of Formula I: ##STR1## wherein R, X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: October 22, 1996
    Assignee: American Cyanamid Company
    Inventors: Joseph M. Backer, Peter Bohlen, Phaik-Eng Sum
  • Patent number: 5563130
    Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein W, R.sub.2 and R.sub.3 are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: October 8, 1996
    Assignee: American Cyanamid Company
    Inventors: Joseph M. Backer, Peter Bohlen
  • Patent number: 5491220
    Abstract: Structural analogues of fibroblast growth factors have an amino acid sequence replacement in the ninth or tenth .beta.-strand of the factor, or the sequence that corresponds to the surface loop that connects the ninth and tenth .beta.-strands, such that the folding of the molecule is not significantly perturbed. Preferred analogues have the amino acid sequence replacement in the surface loop that extends from the ninth .beta.-strand to the tenth .beta.-strand and have the overall secondary and tertiary structure of the original factor, and bind to heparin and a member or members of the fibroblast growth factor receptor family with high affinity. In some embodiments, the analogues are prepared by replacing the surface loop sequence that connects the ninth and tenth .beta.-strand with another amino acid sequence such as a loop sequence from another structurally related fibroblast growth factor or an interleukin.
    Type: Grant
    Filed: August 15, 1994
    Date of Patent: February 13, 1996
    Assignees: Yeda Research and Development Co., Ltd., American Cyanamid Company
    Inventors: Andrew P. Seddon, Luyuan Li, Peter Bohlen, Magdalena Eisinger, Avner Yayon